主要目的：以山东达冠医药科技有限公司提供的克立硼罗软膏为受试制剂，以Anacor Pharmaceuticals, Inc.持证的克立硼罗软膏（商品名：舒坦明®/Staquis®）为参比制剂，评估健康受试者在空腹状态下单次局部外用受试制剂和参比制剂的药代动力学特征，评价两种制剂的人体生物等效性。次要目的：考察健康受试者使用受试制剂和参比制剂后的安全性。

[Translation]

Main purpose: Using the crisaborole ointment provided by Shandong Daguan Pharmaceutical Technology Co., Ltd. as the test preparation and the crisaborole ointment (trade name: Staquis®/Staquis®) licensed by Anacor Pharmaceuticals, Inc. as the reference preparation, the pharmacokinetic characteristics of the test preparation and the reference preparation after single topical application in healthy subjects under fasting state were evaluated, and the bioequivalence of the two preparations in humans was evaluated. Secondary purpose: To investigate the safety of the test preparation and the reference preparation after healthy subjects used them.

Start Date29 Nov 2024

Sponsor / Collaborator

Shandong Daguan Pharmaceutical Technology Co., Ltd.

CTR20244283

/ CompletedNot Applicable

克立硼罗软膏人体生物等效性研究

[Translation] Study on the bioequivalence of crisaborole ointment in healthy volunteers

健康受试者单次外用克立硼罗软膏受试制剂（重庆华邦制药有限公司生产，规格：2%）与参比制剂（持证商Anacor Pharmaceuticals,Inc.）后，评价受试制剂与参比制剂的生物等效性。

[Translation]

The bioequivalence of the test preparation of crisaborole ointment (produced by Chongqing Huabang Pharmaceutical Co., Ltd., specification: 2%) and the reference preparation (licensed manufacturer Anacor Pharmaceuticals, Inc.) was evaluated after a single application of the test preparation to healthy subjects.

Start Date21 Nov 2024

Sponsor / Collaborator

Chongqing Huapont Pharmaceutical Co. Ltd.

CTR20243828

/ Active, not recruitingNot Applicable

克立硼罗软膏在健康受试者中单中心、随机、开放、两制剂、单次给药、两周期、两序列、双交叉空腹生物等效性试验

[Translation] A single-center, randomized, open-label, two-formulation, single-dose, two-cycle, two-sequence, double-crossover fasting bioequivalence study of crisaborole ointment in healthy subjects

主要目的：以药代动力学参数作为主要终点评价指标，比较在空腹状态下外用受试制剂克立硼罗软膏（持证商：河北合渡药业有限公司）与参比制剂克立硼罗软膏（持证商：Anacor Pharmaceuticals, LLC.，商品名：舒坦明®）后在健康受试者体内的药代动力学行为，评价两种制剂的生物等效性。次要目的：（1）观察受试制剂克立硼罗软膏和参比制剂克立硼罗软膏在健康受试者中的安全性；（2）评价受试制剂克立硼罗软膏和参比制剂克立硼罗软膏对健康受试者的皮肤反应性。

[Translation]

Primary objective: To compare the pharmacokinetic behavior of the test preparation crisaborole ointment (licensed by: Hebei Hedu Pharmaceutical Co., Ltd.) and the reference preparation crisaborole ointment (licensed by: Anacor Pharmaceuticals, LLC., trade name: Sutanming®) in healthy subjects after external application in the fasting state, using pharmacokinetic parameters as the primary endpoint evaluation indicators, and to evaluate the bioequivalence of the two preparations. Secondary objectives: (1) To observe the safety of the test preparation crisaborole ointment and the reference preparation crisaborole ointment in healthy subjects; (2) To evaluate the skin reactivity of the test preparation crisaborole ointment and the reference preparation crisaborole ointment in healthy subjects.

Start Date22 Oct 2024

Sponsor / Collaborator

Hebei Hedu Pharmaceutical Co., Ltd.

100 Clinical Results associated with Crisaborole

100 Translational Medicine associated with Crisaborole

100 Patents (Medical) associated with Crisaborole

205

Literatures (Medical) associated with Crisaborole

01 Dec 2024·INTERNATIONAL JOURNAL OF DERMATOLOGY

Disseminated superficial porokeratosis: two case reports of successful treatment with 2% crisaborole ointment

Letter

Author: Xia, Manqi ; Liang, Jingyao ; Liu, Yumei ; Liang, Yimin ; Ye, Qianru

01 Dec 2024·CLINICAL AND EXPERIMENTAL ALLERGY

Topical Anti‐Inflammatory Treatments for Eczema: A Cochrane Systematic Review and Network Meta‐Analysis

Review

Author: Doyle, Megan ; Williams, Hywel C. ; Stuart, Beth ; Futamura, Masaki ; Roberts, Amanda ; Axon, Emma ; Parker, Roses ; Santer, Miriam ; Steele, Lloyd ; Cro, Suzie ; Boyle, Robert J. ; Chu, Derek K. ; Lax, Stephanie J. ; Van Vogt, Eleanor ; Reynolds, Clare ; Candy, Bridget ; Drucker, Aaron M.

ABSTRACT:

Objective:

Eczema is the most burdensome skin condition worldwide and topical anti‐inflammatory treatments are commonly used to control symptoms. The relative effectiveness and safety of different topical anti‐inflammatory treatments is uncertain.

Design:

Network meta‐analysis performed within a Cochrane systematic review to compare and statistically rank efficacy and safety of topical anti‐inflammatory eczema treatments.

Data Sources:

Cochrane Skin Specialised Register, CENTRAL, MEDLINE, Embase and trial registries to June 2023.

Eligibility Criteria for Selected Trials:

Included trials were within‐participant or between‐participant randomised controlled trials. Participants had eczema that was not clinically infected and was not contact dermatitis, seborrheic eczema or hand eczema. Interventions were topical anti‐inflammatory treatments but not complementary treatments, antibiotics alone, wet wraps, phototherapy or systemic treatments. Comparators were no treatment/vehicle or another topical anti‐inflammatory.

Results:

We identified 291 trials (45,846 participants), mainly in high‐income countries. Most were industry‐funded with median 3 weeks treatment duration. Risk of bias assessed using the Cochrane Risk of Bias 2.0 tool was high in 89% of trials, mainly due to risk of selective reporting. Network meta‐analysis of binary outcomes ranked potent and/or very potent topical steroids, tacrolimus 0.1% and ruxolitinib 1.5% among the most effective treatments for improving patient‐reported symptoms (40 trials, all low confidence) and clinician‐reported signs (32 trials, all moderate confidence). For investigator global assessment, the Janus kinas inhibitors ruxolitinib 1.5%, delgocitinib 0.5% or 0.25%, very potent/potent topical steroids and tacrolimus 0.1% were ranked as most effective (140 trials, all moderate confidence). Continuous outcome data were mixed. Local application site reactions were most common with tacrolimus 0.1% (moderate confidence) and crisaborole 2% (high confidence) and least common with topical steroids (moderate confidence). Skin thinning was not increased with short‐term use of any topical steroid potency (low confidence) but skin thinning was reported in 6/2044 (0.3%) participants treated with longer‐term (6–60 months) topical steroids.

Conclusion:

Potent topical steroids, Janus kinase inhibitors and tacrolimus 0.1% were consistently ranked as among the most effective topical anti‐inflammatory treatments for eczema.

01 Dec 2024·EXPERIMENTAL DERMATOLOGY

Characterisation and Profiling of Standard Atopic Dermatitis Therapies in a Chronic Dermatitis Murine Model Induced by Oxazolone

Article

Author: Trincado, Juan L. ; Calama, Elena ; Gavaldà, Amadeu ; Blanco, Ana I. ; Godessart, Nuria ; Nueda, Arsenio ; Gil, Félix ; Aniorte, Gloria

ABSTRACT:

Atopic dermatitis (AD) is a common inflammatory skin disorder characterised by hypersensitivity to allergens, eczematous lesions and pruritus. The aim of this study was to comprehensively characterise a murine model of dermatitis and assess the similarity with the human disease, as well as to profile clinically relevant AD therapies. Four repeated topical administrations of oxazolone in the auricular skin of sensitised mice induced morphological features compatible with AD, including redness and swelling, as well as histological changes typical of spongiotic (eczematous) dermatitis and increased plasmatic IgE. Additionally, key driver Type 2 cytokines involved in the pathophysiology of the disease, IL‐4, IL‐13 and IL − 31, were upregulated in the skin, along with cytokines related to Type 1, 17 and 22 responses, which have been reported to be relevant in the chronic stages of the disease. RNA‐seq studies in OXA model mice samples validate expression changes obtained by q‐PCR and suggest a greater significant similarity with the transcriptomic signature of human AD with respect to psoriasis studies. Oral (cyclosporine, prednisolone and baricitinib) and topical treatments (betamethasone, tacrolimus and crisaborole) were effective inhibiting the induced pathology, as well as modulating the cytokine gene signature of AD. In conclusion, our 4 oxazolone challenges model recapitulates many of the key features of the disease and is responsive to AD standard of care therapies in humans.

News (Medical) associated with Crisaborole

29 Aug 2023

·www.fiercepharma.com

Arcutis launches branded Zoryve ad for a 'Cream That Can' as it eyes streaming services for new campaign

Arcutis Biotherapeutics is looking to compete against Amgen's blockbuster rival Otezla. One year after receiving FDA approval, Arcutis Biotherapeutics is launching the first direct-to-consumer ad campaign for its plaque psoriasis therapy Zoryve. The non-steroid drug competes with Amgen's blockbuster Otezla, which generates more than $2 billion annually and has multiple indications. Otezla was the first pill approved for plaque psoriasis. Arcutis aims to distinguish Zoryve from both topical steroids and Otezla by emphasizing its easier method of administration, which can cover all skin areas. This is in contrast to steroidal creams, which may pose safety risks with prolonged use. This focus is evident in its advertisements The commercial features a simple black background with a central focus on people's naked bodies (without showing their faces). A narrator asks, "For plaque psoriasis, why can't there be a steroid-free topical I can use for as long as I need?" Then a new voice comes in, adding: “A cream I can apply, just once a day,” playing on the “Cream That Can” tagline for the campaign. The "Cream That Can" ad will “air across many of the top on-demand video streaming platforms,” the company said in a release, rather than a full focus on TV. Zoryve (roflumilast) works a topical formulation of the PDE4 inhibitor found in AstraZeneca’s chronic obstructive pulmonary disease treatment Daliresp. The psoriasis med crossed the FDA finish line last August, and Arcutis has been ramping up the unbranded awareness campaigns for the dermatology condition before this new DTC. In September 2022, just weeks after the green light for the med, it launched the “Expose Psoriasis” online educational campaign designed to improve the understanding of plaque psoriasis' physical and emotional impact. It also aimed to raise awareness that symptoms may occur anywhere on the body including knees, elbows, torso and sensitive places like the face and genitals. Before that, in April 2022, Arcutis had also released a survey from the Harris Poll that found 75% of people with psoriasis in intertriginous areas, or skin folds, reported a negative impact on their emotional well-being. “The Cream That Can helps make clear skin the hero. No matter where plaque psoriasis may appear on the skin, whether in hard-to-treat areas like knees and elbows, or sensitive areas like the face and skin folds, Zoryve is the cream that can help,” said Ayisha Jeter, interim chief commercial officer at Arcutis, in a press release. Arcutis is hoping to do better than Pfizer’s Eucrisa, which was set to be the next big topical treatment for inflammatory skin diseases, but the ointment never gained traction in psoriasis thanks to side effects and reimbursement hurdles. But Mizuho analysts are bullish on Zoryve's prospects, which works differently to Eucrisa, and believes the Arcutis med can, with other approvals, hit peak annual sales of between $1.8 billion and $3.8 billion in 2030. In the current psoriasis treatment landscape, next-gen biologics such as Novartis’ Cosentyx, Eli Lilly’s Taltz and AbbVie’s Skyrizi have demonstrated remarkable efficacy in psoriasis. But in an interview with Fierce Pharma last year, Arcutis CEO Frank Watanabe said Zoryve isn’t positioned as a competitor to the biologics but rather as being complementary to them.

Drug Approval

12 Jan 2023

·www.prnewswire.com

AMERICAN ACADEMY OF DERMATOLOGY ISSUES UPDATED GUIDELINES FOR THE MANAGEMENT OF ATOPIC DERMATITIS IN ADULTS WITH TOPICAL THERAPIES

Both well-established and newer topical treatments addressed ROSEMONT, Ill., Jan. 12, 2023 /PRNewswire/ -- Often called eczema or atopic eczema, atopic dermatitis is a common skin condition, affecting 1 in 10 Americans1. Although atopic dermatitis occurs most frequently in children, it also affects adults and can have a significant impact on patients' quality of life. To help ensure that adult patients with atopic dermatitis receive the best possible treatment, the American Academy of Dermatology (AAD) has published updated guidelines of care for the management of atopic dermatitis in adults with topical therapies in the Journal of the American Academy of Dermatology. Continue Reading This is the second in a series of updated guidelines the AAD is producing on the condition. The updates, which outline best practices for topical treatment of the disease, were developed by an expert workgroup of 12 physicians, including 11 dermatologists, an allergist/pediatrician and one patient representative. The AAD published updated guidelines of care for the management of atopic dermatitis in adults with topical therapies Tweet this "Atopic dermatitis is the most common type of eczema, and it can interfere with a person's daily life without proper treatment," said board-certified dermatologist Robert Sidbury, MD, MPH, FAAD, co-chair of the AAD's Atopic Dermatitis Guideline Workgroup. "The guidelines provide evidence-based recommendations for dermatologists to use in caring for their adult atopic dermatitis patients with topical treatments, which have come a long way since the guidelines were last revised in 2014. This update reflects the latest advances in topical medications that are now available to help adults with atopic dermatitis." Atopic dermatitis can develop on any area of your skin at any age. Adults who have atopic dermatitis often have red to dark patches and scaly skin. They also can have extremely dry skin, hand eczema, eye problems, and skin that is easily irritated. "While atopic dermatitis cannot be cured, it can be controlled with proper treatment," said Dr. Sidbury. "A plan created by a board-certified dermatologist can help ease symptoms, reduce flare-ups, and prevent it from worsening. Topical treatments remain one of the most popular options due to their effective track record and overall safety." The Atopic Dermatitis Workgroup developed 12 recommendations on how to manage atopic dermatitis in adults with topical therapies. The workgroup provided new recommendations for non-prescription methods as well as prescription treatments. Strong recommendations were made for topical treatments in which the benefits clearly outweigh the risks and burdens to the patient. These recommendations apply to most patients in most circumstances. Strong recommendations were made for the use of the following: Moisturizers help to relieve patients' dry, cracked skin, decrease inflammation, and reduce the severity of and increase the time between flare-ups. Topical calcineurin inhibitors (pimecrolimus 1% cream and tacrolimus 0.03% or 0.1% ointment) reduce patients' inflammation and itching, as well as decrease their flare-ups. Topical corticosteroids are commonly used as the first-line treatment for patients with atopic dermatitis in all skin regions. They help to relieve itching, decrease inflammation, and can decrease infections. Phosphodiesterase-4 inhibitor (crisaborole ointment) can reduce patients' inflammation, help relieve itching, and decrease infections. Janus kinase inhibitor (ruxolitinib cream) can be used short term to ease the inflammation and itching of patients with mild to moderate atopic dermatitis. The guidelines provide conditional recommendations for the use of bathing and wet wrap therapy. Conditional recommendations apply to most patients, but the most appropriate action may differ depending on individual patient factors. Bathing, followed by moisturization , helps patients hydrate the skin. Bleach baths can help patients prevent infection and get rid of bacteria on their skin. Wet wrap therapy utilizes wet bandages to help hydrate and soothe patients' skin. This treatment provides a barrier against scratching, helps to decrease redness and inflammation, and can reduce the bacteria on patients' skin. "These recommendations are based on the latest evidence-based research on the most effective topical treatments for our patients," said Dawn Davis, MD, FAAD, co-chair of the AAD's Atopic Dermatitis Guideline Workgroup. "These recommended treatments can be used individually or in combination with other treatments." The guidelines made conditional recommendations against the use of topical antimicrobials, antiseptics, and antihistamines due to the low certainty of evidence, which means the true effect may be substantially different from the estimated effect. "These guidelines were updated to enable dermatologists to optimize topical treatments to provide adult atopic dermatitis patients with expert care," said board-certified dermatologist Mark D. Kaufmann MD, FAAD, president of the AAD. "Since each patient's atopic dermatitis is unique, board-certified dermatologists can determine the treatments that will work best for them. I'm very grateful to our workgroup for providing these important updates to help patients worldwide." To find a board-certified dermatologist in your area, visit aad.org/findaderm. More information: Eczema Types: Atopic Dermatitis Overview Eczema Types: Atopic Dermatitis Symptoms Guidelines of care for the management of atopic dermatitis in adults with topical therapies About the AAD 1938, is the largest, most influential and most representative of all dermatologic associations. With a membership of more than 20,000 physicians worldwide, the AAD is committed to advancing the diagnosis and medical, surgical and cosmetic treatment of the skin, hair and nails; advocating high standards in clinical practice, education and research in dermatology; and supporting and enhancing patient care because skin, hair, and nail conditions can have a serious impact on your health and well-being. For more information, contact the AAD at (888) 462-DERM (3376) or aad.org. Follow @AADskin on Facebook, Pinterest and YouTube and @AADskin1 on Instagram. About JAAD The Journal of the American Academy of Dermatology is the most widely read dermatology journal in the world, according to Kantar Media. JAAD was the first most-cited dermatology journal in 2021, according to impact factor rankings from Clarivate's Journal Citation Reports (JCR) Web of Science Group. JAAD also has two open-access companion titles: JAAD Case Reports and JAAD International. Follow @JAADJournals on Facebook, Twitter, and Instagram. SOURCE American Academy of Dermatology

12 Jan 2023

·www.biospace.com

American Academy of Dermatology Issues Updated Guidelines for the Management of Atopic Dermatitis in Adults With Topical Therapies

Both well-established and newer topical treatments addressed ROSEMONT, Ill., Jan. 12, 2023 /PRNewswire/ -- Often called eczema or atopic eczema, atopic dermatitis is a common skin condition, affecting 1 in 10 Americans1. Although atopic dermatitis occurs most frequently in children, it also affects adults and can have a significant impact on patients' quality of life. To help ensure that adult patients with atopic dermatitis receive the best possible treatment, the American Academy of Dermatology (AAD) has published updated guidelines of care for the management of atopic dermatitis in adults with topical therapies in the Journal of the American Academy of Dermatology. The AAD published updated guidelines of care for the management of atopic dermatitis in adults with topical therapies This is the second in a series of updated guidelines the AAD is producing on the condition. The updates, which outline best practices for topical treatment of the disease, were developed by an expert workgroup of 12 physicians, including 11 dermatologists, an allergist/pediatrician and one patient representative. "Atopic dermatitis is the most common type of eczema, and it can interfere with a person's daily life without proper treatment," said board-certified dermatologist Robert Sidbury, MD, MPH, FAAD, co-chair of the AAD's Atopic Dermatitis Guideline Workgroup. "The guidelines provide evidence-based recommendations for dermatologists to use in caring for their adult atopic dermatitis patients with topical treatments, which have come a long way since the guidelines were last revised in 2014. This update reflects the latest advances in topical medications that are now available to help adults with atopic dermatitis." Atopic dermatitis can develop on any area of your skin at any age. Adults who have atopic dermatitis often have red to dark patches and scaly skin. They also can have extremely dry skin, hand eczema, eye problems, and skin that is easily irritated. "While atopic dermatitis cannot be cured, it can be controlled with proper treatment," said Dr. Sidbury. "A plan created by a board-certified dermatologist can help ease symptoms, reduce flare-ups, and prevent it from worsening. Topical treatments remain one of the most popular options due to their effective track record and overall safety." The Atopic Dermatitis Workgroup developed 12 recommendations on how to manage atopic dermatitis in adults with topical therapies. The workgroup provided new recommendations for non-prescription methods as well as prescription treatments. Strong recommendations were made for topical treatments in which the benefits clearly outweigh the risks and burdens to the patient. These recommendations apply to most patients in most circumstances. Strong recommendations were made for the use of the following: Moisturizers help to relieve patients' dry, cracked skin, decrease inflammation, and reduce the severity of and increase the time between flare-ups. Topical calcineurin inhibitors (pimecrolimus 1% cream and tacrolimus 0.03% or 0.1% ointment) reduce patients' inflammation and itching, as well as decrease their flare-ups. Topical corticosteroids are commonly used as the first-line treatment for patients with atopic dermatitis in all skin regions. They help to relieve itching, decrease inflammation, and can decrease infections. Phosphodiesterase-4 inhibitor (crisaborole ointment) can reduce patients' inflammation, help relieve itching, and decrease infections. Janus kinase inhibitor (ruxolitinib cream) can be used short term to ease the inflammation and itching of patients with mild to moderate atopic dermatitis. The guidelines provide conditional recommendations for the use of bathing and wet wrap therapy. Conditional recommendations apply to most patients, but the most appropriate action may differ depending on individual patient factors. Bathing, followed by moisturization, helps patients hydrate the skin. Bleach baths can help patients prevent infection and get rid of bacteria on their skin. Wet wrap therapy utilizes wet bandages to help hydrate and soothe patients' skin. This treatment provides a barrier against scratching, helps to decrease redness and inflammation, and can reduce the bacteria on patients' skin. "These recommendations are based on the latest evidence-based research on the most effective topical treatments for our patients," said Dawn Davis, MD, FAAD, co-chair of the AAD's Atopic Dermatitis Guideline Workgroup. "These recommended treatments can be used individually or in combination with other treatments." The guidelines made conditional recommendations against the use of topical antimicrobials, antiseptics, and antihistamines due to the low certainty of evidence, which means the true effect may be substantially different from the estimated effect. "These guidelines were updated to enable dermatologists to optimize topical treatments to provide adult atopic dermatitis patients with expert care," said board-certified dermatologist Mark D. Kaufmann MD, FAAD, president of the AAD. "Since each patient's atopic dermatitis is unique, board-certified dermatologists can determine the treatments that will work best for them. I'm very grateful to our workgroup for providing these important updates to help patients worldwide." To find a board-certified dermatologist in your area, visit aad.org/findaderm. More information: Eczema Types: Atopic Dermatitis Overview Eczema Types: Atopic Dermatitis Symptoms Guidelines of care for the management of atopic dermatitis in adults with topical therapies About the AAD 1938, is the largest, most influential and most representative of all dermatologic associations. With a membership of more than 20,000 physicians worldwide, the AAD is committed to advancing the diagnosis and medical, surgical and cosmetic treatment of the skin, hair and nails; advocating high standards in clinical practice, education and research in dermatology; and supporting and enhancing patient care because skin, hair, and nail conditions can have a serious impact on your health and well-being. For more information, contact the AAD at (888) 462-DERM (3376) or aad.org. Follow @AADskin on Facebook, Pinterest and YouTube and @AADskin1 on Instagram. About JAAD The Journal of the American Academy of Dermatology is the most widely read dermatology journal in the world, according to Kantar Media. JAAD was the first most-cited dermatology journal in 2021, according to impact factor rankings from Clarivate's Journal Citation Reports (JCR) Web of Science Group. JAAD also has two open-access companion titles: JAAD Case Reports and JAAD International. Follow @JAADJournals on Facebook, Twitter, and Instagram. View original content: SOURCE American Academy of Dermatology

100 Deals associated with Crisaborole

External Link

KEGG	Wiki	ATC	Drug Bank
D10873	Crisaborole	D11AH06	DB05219

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Dermatitis, Atopic	US	Anacor Pharmaceuticals LLC	14 Dec 2016

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Mild Atopic Dermatitis	Phase 3	US	Pfizer Inc.	12 Sep 2019
Mild Atopic Dermatitis	Phase 3	US	Huizhi Pharmaceutical (Dalian) Co., Ltd.	12 Sep 2019
Mild Atopic Dermatitis	Phase 3	CN	Pfizer Inc.	12 Sep 2019
Mild Atopic Dermatitis	Phase 3	AU	Huizhi Pharmaceutical (Dalian) Co., Ltd.	12 Sep 2019
Mild Atopic Dermatitis	Phase 3	AU	Pfizer Inc.	12 Sep 2019
Mild Atopic Dermatitis	Phase 3	AT	Anacor Pharmaceuticals LLC	12 Sep 2019
Mild Atopic Dermatitis	Phase 3	AT	Pharmacia & Upjohn Co. LLC	12 Sep 2019
Mild Atopic Dermatitis	Phase 3	AT	Huizhi Pharmaceutical (Dalian) Co., Ltd.	12 Sep 2019
Mild Atopic Dermatitis	Phase 3	AT	Pfizer Investment Co. Ltd.	12 Sep 2019
Mild Atopic Dermatitis	Phase 3	CA	Huizhi Pharmaceutical (Dalian) Co., Ltd.	12 Sep 2019

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT03832010 (CTgov)	Phase 4	Eczema \| Dermatitis, Atopic	24	Aquaphor+Triamcinolone ointment+Hydrocortisone Ointment+Crisaborole (Crisaborole)	yyrfgjmuxt(imurzldjzy) = itpktzakyy nkabhrfmaz (oyzersytsd, uqryivrmty - xlxjmwwfli) View more	-	19 Jul 2024
				Aquaphor+Triamcinolone ointment+Hydrocortisone Ointment (Vehicle)	yyrfgjmuxt(imurzldjzy) = jagidatenk nkabhrfmaz (oyzersytsd, zvobzhskdk - vqpxsuelhx) View more
NCT04360187 (CrisADe CLEAR, Pubmed) Manual	Phase 3	Dermatitis, Atopic	237	Crisaborole ointment, 2%	etrxswwslo(fxftknrzgf) = oinrukjnrj cyaauygvet (rvydenjuqh, 35.4 - 51.1) View more	Positive	01 May 2024
				Vehicle	etrxswwslo(fxftknrzgf) = bpqkmlmeub cyaauygvet (rvydenjuqh, 22.5 - 44.2) View more
NCT04040192 (CrisADe CONTROL, Pubmed) Manual	Phase 3	Dermatitis, Atopic Maintenance	250	Crisaborole QD	rhrofbrkvx(rcjefmpqkc) = 41.5 days twizpyffgz (pnkcgowaxa )	Positive	28 Mar 2024
				Vehicle
NCT04040192 (CrisADe CONTROL, EADV2023)	Phase 3	Dermatitis, Atopic	497	Crisaborole BID	nhpynjvvwx(jyflaazmxu) = tyerwmzikb apytfjoqed (ttrlwncgih, 48.7 - 64.0)	Positive	11 Oct 2023
NCT04040192 (CrisADe CONTROL, EADV2023)	Phase 3	Dermatitis, Atopic Maintenance	497	Crisaborole QD	iqcllddjpf(uukakdejez) = qxvmhiddjc svlakloagj (muimgterkh ) View more	-	11 Oct 2023
				Vehicle QD	iqcllddjpf(uukakdejez) = flaaklapww svlakloagj (muimgterkh ) View more
WCD2023	Not Applicable	Tracheitis	13	Crisaborole	hczxrwnbuf(nkxhjekdjv) = eomuhllszx dqdrrztifj (aarmzmcvrk ) View more	Positive	07 Jul 2023
WCD2023	Not Applicable	Dermatitis, Atopic	-	Crisaborole	brgahopnjb(fvvqhncipu) = atjfexsnok mfqjszbyus (wuvyuvibdu )	-	03 Jul 2023
				Vehicle	vhalrcglfn(ugbbfoiwgw) = zsixrdhdpu ujoqwvxhfn (mtygpwrdmo ) View more
NCT04194814 (WCD2023)	Phase 2	Dermatitis, Atopic	37	Betamethasone valerate	lpwooivowy(lcgqilrykg) = pvwcnlvouj zgvedtrwip (sbgjzkmwrb, 14.93 - 20.86)	-	03 Jul 2023
NCT04040192 (CrisADe CONTROL, Pubmed)	Phase 3	Dermatitis, Atopic Maintenance	497	Crisaborole QD	okkutcomit(ehbkjnrdth) = otcnohxsqa ehojxthfap (kfddcrndwx )	Positive	15 May 2023
				Vehicle QD	okkutcomit(ehbkjnrdth) = pjapbbwbjj ehojxthfap (kfddcrndwx )
NCT04040192 (CrisADe CONTROL, CTgov)	Phase 3	Moderate Atopic Dermatitis \| Mild Atopic Dermatitis	620	crisaborole (Vehicle QD)	tzpvfhmpvp(dclwvqtocn) = bafgdhtadk umdlxzaegd (mcgppixjxs, xrvkzjpkgw - qtkrjnxsol) View more	-	08 Mar 2023
				Crisaborole (Crisaborole 2% QD)	tzpvfhmpvp(dclwvqtocn) = fnfsmwwtxm umdlxzaegd (mcgppixjxs, bcbdixuwme - uxourgduzt) View more

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis